PRT-12396

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NamePRT-12396
Drug Alias NamePRT12396PRT-12396
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJAK2 V617F inhibitors
TargetsJAK2 V617F
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocythemia, Essential +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrelude Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIncyte CorpPrelude Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocythemia, Essential +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A